Skip to main content
Clinical Trials/NCT02426788
NCT02426788CompletedNot Applicable

The PRINCE Secondary Study: Persistent Physical Symptoms Reduction Intervention: a System Change and Evaluation in Secondary Care

King's College London7 sites in 1 country324 target enrollmentStarted: July 2015Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
324
Locations
7
Primary Endpoint
Work and social adjustment scale

Study Overview

Brief Summary

Brief Summary: Persistent Physical Symptoms (PPS), also known as medically unexplained symptoms (MUS) is a term used to describe a range of persistent bodily symptoms for which the exact cause is unclear. Between 20 and 40% of patients in primary care, and about 50% in secondary care experience PPS. Not only are PPS common, but the overlap across different patient groups may indicate that these phenomena are transdiagnostic. PPS are associated with profound disability and high health care costs, and if left untreated the prognosis of these patients is poor. There is an accumulating body of evidence demonstrating that cognitive behavioural interventions can reduce levels of symptoms and improve functioning in patients with PPS. A pragmatic randomised controlled trial (RCT) was designed to evaluate the clinical and cost-effectiveness of cognitive behavioural therapy (CBT) + Standard Medical Care (SMC) versus Standard Medical Care alone, in the treatment of patients with PPS. The trial will focus on patients with a variety of symptoms (e.g., non-cardiac chest pain, fibromyalgia), across secondary care clinics (e.g., neurology, cardiology, and rheumatology).

Detailed Description

Background and study aims In primary care between 20 and 40% of patients have medically unexplained physical symptoms. The term medically unexplained symptoms (MUS) is commonly used by health care professionals. However a survey of a healthy population and a separate survey of patients with chronic fatigue syndrome (CFS) suggested that the term persistent physical symptoms (PPS) was the preferred term. The term PPS may have its drawbacks, but it will be used in the rest of this document to cover MUS as well as any other terms that may be used in the literature and clinical settings to refer to these symptoms. In secondary care, about 50% of patients have PPS, in many specialties. PPS are associated with profound disability and high health care costs. Around 50% of sufferers have co-morbid anxiety and depression and sleep problems. Left untreated, the prognosis of these patients is poor.

This study is a pragmatic RCT that will evaluate the clinical and cost-effectiveness of cognitive behavioural therapy + standard medical care (CBT+SMC), which involves 8 sessions of CBT, versus standard medical care (SMC) in the treatment of patients with PPS.

Who can participate? Patients with various PPS, such as fibromyalgia, non-cardiac chest pain, irritable bowel syndrome and a range of neurological symptoms e.g., weakness will be recruited. Participants will be recruited from clinics in secondary care (e.g., neurology, cardiology, rheumatology) at various hospitals in London.

What does the study involve? Potential participants will be identified by clinical staff who will refer them to the research team. Patients who give their consent to take part in the study will complete a number of questionnaires asking about their symptoms and use of health care services, and about their thoughts, feelings, and beliefs related to their PPS (i.e., baseline). This will take approximately 1.5 hours. After this research assessment, half of participants will be randomly assigned to the treatment arm (CBT+SMC), or to the control (SMC) arm. Participants in the treatment arm will receive 8 individual sessions of CBT (weekly or fortnightly sessions). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve their quality of life. Participants in the SMC group will receive usual medical care within the clinic.

Participants in both arms will also be asked to complete questionnaires at 9, 20, 40, and 52 weeks after randomisation. The assessment will be independent of the health care professionals delivering care.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Active psychosis;
  • Factitious disorder;
  • Headaches as the only PPS;
  • Non-epileptic seizures
  • Current alcohol dependence or drug addiction as assessed by the clinician;
  • Current benzodiazepine use exceeding the equivalent of 10mg diazepam/day;
  • The patient is currently receiving CBT/CBT based approach psychotherapy, or has received CBT/CBT based approach psychotherapy in the past year, for their PPS;
  • The patient is thought to be at imminent risk of self-harm;
  • Patient is taking part in PRINCE Primary trial.

Arms & Interventions

CBT+SMC

Experimental

Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):

8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly.

Intervention: Cognitive behavioural therapy (CBT) (Behavioral)

Standard Medical Care (SMC)

No Intervention

Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.

Outcomes

Primary Outcomes

Work and social adjustment scale

Time Frame: 52 weeks post randomisation

Measures impairment in functioning

Secondary Outcomes

  • Patient Health Questionnaire-9 (PHQ-9)(52 weeks post randomisation)
  • Generalized Anxiety Disorder-7 (GAD-7)(52 weeks post randomisation)
  • Clinical Global Impression (CGI)(52 weeks post randomisation)
  • Cognitive Behavioural Responses Questionnaire(52 weeks post randomisation)
  • Patient Health Questionnaire-15 (PHQ-15)(52 weeks post randomisation)
  • Client Service Receipt Inventory (CSRI)(52 weeks post randomisation)
  • Persistent Physical Symptom Questionnaire(52 weeks post randomisation)
  • EuroQol-5D (EQ-5D)(52 weeks post randomisation)
  • Acceptance scale(52 weeks post randomisation)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (7)

Loading locations...

Similar Trials